139 related articles for article (PubMed ID: 11148501)
21. Combination chemotherapy in the tumour stage of mycosis fungoides with cyclophosphamide, vincristine, vp-16, adriamycin and prednisolone (cop, chop, cavop): a report from the Scandinavian mycosis fungoides study group.
Molin L; Thomsen K; Volden G; Groth O; Hellbe L; Holst R; Knudsen EA; Roupe G; Schmidt H
Acta Derm Venereol; 1980; 60(6):542-4. PubMed ID: 6162347
[TBL] [Abstract][Full Text] [Related]
22. Clinical experience: practical management of five patients with cutaneous T-cell lymphoma (CTCL)-related symptoms.
Dummer R; Foss F; Dreno B; Bagot M
Semin Oncol; 2006 Feb; 33(1 Suppl 3):S26-32. PubMed ID: 16516673
[TBL] [Abstract][Full Text] [Related]
23. Imiquimod 5% cream in the treatment of mycosis fungoides--a pilot study.
Chong A; Loo WJ; Banney L; Grant JW; Norris PG
J Dermatolog Treat; 2004 Apr; 15(2):118-9. PubMed ID: 15204164
[No Abstract] [Full Text] [Related]
24. Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas.
de Masson A; Guitera P; Brice P; Moulonguet I; Mouly F; Bouaziz JD; Battistella M; Madelaine I; Roux J; Ram-Wolff C; Cayuela JM; Bachelez H; Bensussan A; Michel L; Bagot M
Br J Dermatol; 2014 Mar; 170(3):720-4. PubMed ID: 24438061
[TBL] [Abstract][Full Text] [Related]
25. Successful treatment of primary cutaneous follicle centre lymphoma with topical 5% imiquimod.
Stavrakoglou A; Brown VL; Coutts I
Br J Dermatol; 2007 Sep; 157(3):620-2. PubMed ID: 17553050
[No Abstract] [Full Text] [Related]
26. Evaluation of O6-Benzylguanine-Potentiated Topical Carmustine for Mycosis Fungoides: A Phase 1-2 Clinical Trial.
Tacastacas JD; Chan DV; Carlson S; Gerson SL; Dowlati A; Fu P; Lu K; Groft S; Rosenjack J; Honda K; McCormick TS; Cooper KD
JAMA Dermatol; 2017 May; 153(5):413-420. PubMed ID: 28199478
[TBL] [Abstract][Full Text] [Related]
27. Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma.
Kim YH; Girardi M; Duvic M; Kuzel T; Link BK; Pinter-Brown L; Rook AH
J Am Acad Dermatol; 2010 Dec; 63(6):975-83. PubMed ID: 20888065
[TBL] [Abstract][Full Text] [Related]
28. Granulomatous slack skin: a distinct disorder or a variant of mycosis fungoides?
Topar G; Zelger B; Schmuth M; Romani N; Thaler J; Sepp N
Acta Derm Venereol; 2001; 81(1):42-4. PubMed ID: 11411914
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of single-agent chemotherapy with pegylated liposomal doxorubicin or gemcitabine in a diverse cohort of patients with recalcitrant cutaneous T-cell lymphoma.
Weiner D; Ly A; Talluru S; Munjal A; Pierog O; Ambinder R; Rozati S
Br J Dermatol; 2024 Feb; 190(3):436-438. PubMed ID: 37655919
[No Abstract] [Full Text] [Related]
30. Skin-Directed Therapies in Cutaneous T-Cell Lymphoma.
Nguyen CV; Bohjanen KA
Dermatol Clin; 2015 Oct; 33(4):683-96. PubMed ID: 26433841
[TBL] [Abstract][Full Text] [Related]
31. Long-term control of mycosis fungoides of the hands with topical bexarotene: an update 15 years later.
Ramachandran V; Park KE; Duvic M
Int J Dermatol; 2019 Nov; 58(11):e221-e222. PubMed ID: 31209865
[No Abstract] [Full Text] [Related]
32. Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial.
Wollina U; Looks A; Meyer J; Knopf B; Koch HJ; Liebold K; Hipler UC
J Am Acad Dermatol; 2001 Feb; 44(2):253-60. PubMed ID: 11174383
[TBL] [Abstract][Full Text] [Related]
33. [Cutaneous T-cell lymphoma bullosa: 2 cases].
Héliot I; Beylot-Barry M; Vergier B; Doutre MS; Beylot C
Ann Dermatol Venereol; 2003; 130(6-7):639-42. PubMed ID: 13679703
[TBL] [Abstract][Full Text] [Related]
34. Mycosis fungoides lymphoma.
Van Scott EJ
Clin Pharmacol Ther; 1974 Nov; 16(5 Part 2):931-3. PubMed ID: 4424203
[No Abstract] [Full Text] [Related]
35. Long-term follow-up in 51 patients with mycosis fungoides and Sézary syndrome treated by interferon-alfa.
Jumbou O; N'Guyen JM; Tessier MH; Legoux B; Dréno B
Br J Dermatol; 1999 Mar; 140(3):427-31. PubMed ID: 10233261
[TBL] [Abstract][Full Text] [Related]
36. Treatment of cutaneous T-cell lymphoma with the arotinoid Ro 13-6298.
Tousignant J; Raymond GP; Light MJ
J Am Acad Dermatol; 1987 Jan; 16(1 Pt 2):167-71. PubMed ID: 3493269
[TBL] [Abstract][Full Text] [Related]
37. Treatment of cutaneous T-cell lymphoma with alitretinoin gel.
Bassiri-Tehrani S; BA BA; Cohen DE
Int J Dermatol; 2002 Feb; 41(2):104-6. PubMed ID: 11982647
[No Abstract] [Full Text] [Related]
38. Complete remission of a radio-resistant cutaneous angiosarcoma of the scalp by systemic treatment with liposomal doxorubicin.
Eiling S; Lischner S; Busch JO; Rothaupt D; Christophers E; Hauschild A
Br J Dermatol; 2002 Jul; 147(1):150-3. PubMed ID: 12100199
[TBL] [Abstract][Full Text] [Related]
39. Vorinostat (Zolinza) for cutaneous T-Cell lymphoma.
Med Lett Drugs Ther; 2007 Mar; 49(1256):23-4. PubMed ID: 17351559
[No Abstract] [Full Text] [Related]
40. Bexarotene reverses alopecia in cutaneous T-cell lymphoma.
Hanson M; Hill A; Duvic M
Br J Dermatol; 2003 Jul; 149(1):193-6. PubMed ID: 12890219
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
